These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 2249373)

  • 1. The contribution of N-hydroxylation and acetylation to dapsone pharmacokinetics in normal subjects.
    May DG; Porter JA; Uetrecht JP; Wilkinson GR; Branch RA
    Clin Pharmacol Ther; 1990 Dec; 48(6):619-27. PubMed ID: 2249373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of dapsone toxicity in patients with inflammatory dermatoses: activity of acetylation and hydroxylation of dapsone as risk factors.
    Bluhm RE; Adedoyin A; McCarver DG; Branch RA
    Clin Pharmacol Ther; 1999 Jun; 65(6):598-605. PubMed ID: 10391665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The disposition of dapsone in cirrhosis.
    May DG; Arns PA; Richards WO; Porter J; Ryder D; Fleming CM; Wilkinson GR; Branch RA
    Clin Pharmacol Ther; 1992 Jun; 51(6):689-700. PubMed ID: 1611807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intra-adipose administration of monoacetyldapsone to healthy volunteers.
    Pieters FA; Zuidema J
    Int J Lepr Other Mycobact Dis; 1986 Dec; 54(4):510-6. PubMed ID: 3819527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequency distribution of dapsone N-hydroxylase, a putative probe for P4503A4 activity, in a white population.
    May DG; Porter J; Wilkinson GR; Branch RA
    Clin Pharmacol Ther; 1994 May; 55(5):492-500. PubMed ID: 8181193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reassessment of dapsone as a marker of acetylator phenotypes.
    Wiggan EB; Dennis S; Reele SB; Luke DR
    Int J Clin Pharmacol Ther Toxicol; 1991 Jul; 29(7):262-8. PubMed ID: 1889912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolism of dapsone to its hydroxylamine by CYP2E1 in vitro and in vivo.
    Mitra AK; Thummel KE; Kalhorn TF; Kharasch ED; Unadkat JD; Slattery JT
    Clin Pharmacol Ther; 1995 Nov; 58(5):556-66. PubMed ID: 7586950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of effect of proguanil on the pharmacokinetics of dapsone in healthy volunteers.
    Edstein MD; Rieckmann KH
    Chemotherapy; 1993; 39(4):235-41. PubMed ID: 8325124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N-acetylation polymorphism of dapsone in a Japanese population.
    Horai Y; Ishizaki T
    Br J Clin Pharmacol; 1988 Apr; 25(4):487-94. PubMed ID: 3382590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of acetylation and deacetylation on the disposition of dapsone and monoacetyl dapsone hydroxylamines in human erythrocytes in-vitro.
    Coleman MD; Pahal KK; Gardiner JM
    J Pharm Pharmacol; 1996 Apr; 48(4):401-6. PubMed ID: 8794991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. N-acetylation phenotyping with dapsone in a mainland Chinese population.
    Horai Y; Zhou HH; Zhang LM; Ishizaki T
    Br J Clin Pharmacol; 1988 Jan; 25(1):81-7. PubMed ID: 3370194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. N-acetylation phenotyping using dapsone in a Jordanian population.
    Irshaid YM; al-Hadidi HF; Abuirjeie MA; Rawashdeh NM
    Br J Clin Pharmacol; 1991 Sep; 32(3):289-93. PubMed ID: 1777365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simultaneous analysis of dapsone and monoacetyldapsone employing high performance liquid chromatography: a rapid method for determination of acetylator phenotype.
    Carr K; Oates JA; Nies AS; Woosley RL
    Br J Clin Pharmacol; 1978 Nov; 6(5):421-7. PubMed ID: 728285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gonadal influence on the metabolism and haematological toxicity of dapsone in the rat.
    Coleman MD; Tingle MD; Winn MJ; Park BK
    J Pharm Pharmacol; 1990 Oct; 42(10):698-703. PubMed ID: 1982141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of cimetidine as a selective inhibitor of dapsone N-hydroxylation in man.
    Coleman MD; Scott AK; Breckenridge AM; Park BK
    Br J Clin Pharmacol; 1990 Nov; 30(5):761-7. PubMed ID: 2271376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoacetyldapsone inhibition of dapsone N-hydroxylation by human and rat liver microsomes.
    Irshaid Y; Adedoyin A; Lotze M; Branch RA
    Drug Metab Dispos; 1994; 22(1):161-4. PubMed ID: 8149877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of trimetrexate and dapsone in AIDS patients with Pneumocystis carinii pneumonia.
    Koda RT; Dubé MP; Li WY; Chatterjee DJ; Stansell JD; Sattler FR
    J Clin Pharmacol; 1999 Mar; 39(3):268-74. PubMed ID: 10073326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple-dose pharmacokinetics and in vitro antimalarial activity of dapsone plus pyrimethamine (Maloprim) in man.
    Edstein MD; Rieckmann KH; Veenendaal JR
    Br J Clin Pharmacol; 1990 Aug; 30(2):259-65. PubMed ID: 2206787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of clarithromycin, fluconazole, and rifabutin on dapsone hydroxylamine formation in individuals with human immunodeficiency virus infection (AACTG 283).
    Winter HR; Trapnell CB; Slattery JT; Jacobson M; Greenspan DL; Hooton TM; Unadkat JD
    Clin Pharmacol Ther; 2004 Dec; 76(6):579-87. PubMed ID: 15592329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Formation and elimination of sulphamethoxazole hydroxylamine after oral administration of sulphamethoxazole.
    van der Ven AJ; Mantel MA; Vree TB; Koopmans PP; van der Meer JW
    Br J Clin Pharmacol; 1994 Aug; 38(2):147-50. PubMed ID: 7981016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.